Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Insmed ( (INSM) ) has shared an update.
On June 6, 2025, Insmed Incorporated completed the redemption of its 0.75% Convertible Senior Notes due 2028. The redemption involved paying cash for outstanding notes totaling $1,965,204.69, fulfilling the terms of the Indenture agreement.
The most recent analyst rating on (INSM) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
Insmed’s stock score is driven by financial challenges and valuation concerns despite positive earnings call outcomes and supportive corporate events. Revenue growth and clinical advancements are offset by high debt and cash flow deficits.
To see Spark’s full report on INSM stock, click here.
More about Insmed
Average Trading Volume: 2,289,819
Technical Sentiment Signal: Buy
Current Market Cap: $13.42B
For detailed information about INSM stock, go to TipRanks’ Stock Analysis page.